Oricidin Launches Groundbreaking Dental Gel for Long-Term Periodontitis Treatment
Rhea-AI Summary
Orocidin A/S, a subsidiary of Nordicus Partners (NORD), has introduced a breakthrough dental gel for long-term periodontitis treatment. The innovative low-viscosity gel features a unique active peptide and is designed for direct application into dental pockets by dentists using a syringe and flushing cannula.
The gel's key innovation lies in its formulation of triglycerides, monoglycerides, and water. Upon contact with oral cavity moisture, it forms a semi-solid bioadhesive crystalline matrix, enabling slow and localized release of the active ingredient. All components are biocompatible and FDA-approved for oral use.
Positive
- Development of innovative dental gel product for periodontitis treatment
- FDA-approved components for oral use
- Proprietary technology for controlled drug release
Negative
- No revenue projections or market size estimates provided
- No timeline for commercial launch mentioned
- No clinical trial data or efficacy results presented
BEVERLY HILLS, California, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S, a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, has developed a novel, proprietary dental gel that represents a significant breakthrough in the long-term treatment of periodontitis.
This innovative low-viscosity gel, featuring a unique active ingredient, offers an effective and convenient solution for long-term management of this widespread oral health condition. The gel is applied by dentists using a syringe and flushing cannula to deliver the treatment directly into dental pockets. Upon contact with oral cavity moisture, the gel forms a semi-solid, bioadhesive crystalline matrix. This structure enables the slow and localized release of the active peptide, ensuring sustained treatment efficacy over time.
The formulation leverages an optimized ratio of triglycerides, monoglycerides, and water. When exposed to water naturally present in the oral cavity, the gel rapidly forms a semi-solid bioadhesive crystalline matrix, enabling the slow, localized release of the active peptide for effective, long-term treatment of periodontitis. All components are biocompatible and FDA-approved for oral use, ensuring safety and effectiveness for patients.
“Oricidin’s innovative dental gel represents a significant advancement in the treatment of periodontitis,” said Allan Wehnert, Founder and CEO of Orocidin. “By combining cutting-edge science with patient-centered design, we aim to improve both outcomes and the overall dental care experience,”.
For further information, contact:
Mr. Henrik Rouf
Chief Executive Officer
Phone +1 310 666 0750
Email hr@nordicuspartners.com
Investor Relations
Jonathan Paterson
Harbor Access Investor Relations
Jonathan.Paterson@Harbor-Access.com
Tel +1 475 477 9401
About Nordicus Partners Corporation
Nordicus Partners Corporation is the only U.S. publicly traded business accelerator and holding company for Nordic life sciences companies. Leveraging decades of combined management experience in domestic and global corporate sectors, Nordicus excels in corporate finance activities including business and market development, growth strategies, talent acquisition, partnership building, capital raising, and facilitating company acquisitions and sales. In 2024, Nordicus acquired
Cautionary Note Regarding Forward-Looking Statements:
This press release may contain forward-looking statements that involve substantial risks and uncertainties. You can identify these statements by the use of forward-looking terminology such as “may,” “will,” “should,” “expect,” “anticipate,” “project,” “estimate,” “intend,” “continue” or “believe” or the negatives thereof or other variations thereon or comparable terminology. You should read statements that contain these words carefully because they discuss our plans, strategies, prospects and expectations concerning our business, operating results, financial condition and other similar matters. We believe that it is important to communicate our future expectations to our investors. There may be events in the future, however, that we are not able to predict accurately or control. Any forward-looking statement made by us in this press release speaks only as of the date on which we make it. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
FAQ
What is the new dental gel product announced by Nordicus Partners (NORD) in January 2025?
How does Orocidin's new dental gel technology work for periodontitis treatment?
Are the components in NORD's new dental gel FDA-approved?
What is the delivery method for Orocidin's new periodontitis treatment?
